We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HIL-214

News List

Takeda and Frazier Healthcare Partners collaborate to develop clinical-stage norovirus vaccine candidate expresspharma
August 03, 2021
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate.
Takeda and Frazier to launch HilleVax for norovirus vaccine development pharmaceutical-technology
August 02, 2021
Takeda Pharmaceutical and Frazier Healthcare Partners have partnered to launch a biopharmaceutical company named HilleVax to develop and market Takeda’s norovirus vaccine candidate, HIL-214 (previously TAK-214).